{
    "N/R/U": null,
    "Applicant": "Amneal Pharmaceuticals LLC",
    "BLA Number": "761231",
    "Proprietary Name": "Alymsys",
    "Proper Name": "bevacizumab-maly",
    "BLA Type": "351(k) Biosimilar",
    "Strength": "100MG/4ML (25MG/ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Intravenous",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "April 13, 2022",
    "Ref. Product Proper Name": "bevacizumab",
    "Ref. Product Proprietary Name": "Avastin",
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "2241",
    "Product Number": "001",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null
}